Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• V gamma 9 V delta 2 T cells possess potent anti-tumoral activity mediated by T cell receptor and natural killer receptors.
• These gammadelta T cells can recognize and eliminate a broad spectrum of tumor cells.

Purpose of the Study:

• To explore the potential of aminobisphosphonates for in vivo activation of gammadelta T cells.
• To discuss the implications for developing novel cancer immunotherapies.

Main Methods:

• Review of in vitro and in vivo studies demonstrating gammadelta T cell anti-tumoral effects.
• Discussion of clinical translation of gammadelta T cell-based therapies.

Main Results:

• Gammadelta T cells show significant anti-tumoral effects both in laboratory settings and in living organisms.
• This suggests a viable new therapeutic strategy for clinical application.

Conclusions:

• V gamma 9 V delta 2 T lymphocytes are a key target for immunotherapy using N-aminobisphosphonates.
• Phase I-II clinical trials are actively investigating zoledronic acid combined with IL-2 for solid tumors.